Scientific deep-dive
Burping, Reflux and Gas on a GLP-1: The Label's Widest Gap
Eructation runs under 1% on placebo against 7% on Wegovy — a sevenfold difference, and the widest relative gap in the adverse-reactions table. Reflux is a much smaller increase than people expect.
Nausea gets the warnings. Burping does not, and it has the widest relative gap in the entire adverse-reactions table: under 1% on placebo against 7% on Wegovy.[1] That is a sevenfold difference, where nausea — the effect everyone is told about — is under threefold. If you started one of these and found yourself burping in a way you never did before, that is the drug, it is in the label, and nobody mentioned it.
The numbers, side by side
| Effect | Placebo | Wegovy | Relative gap |
|---|---|---|---|
| Eructation (burping) | <1% | 7% | More than sevenfold |
| Dyspepsia (indigestion) | 3% | 9% | Threefold |
| Abdominal distension (bloating) | 5% | 7% | Modest |
| Flatulence | 4% | 6% | Modest |
| Gastroesophageal reflux | 3% | 5% | Modest |
Reflux is worth separating from the rest. At 5% against 3% it is a real but modest increase — considerably less dramatic than the burping figure, and less than many people expect given how much is written about it.
Why a drug that slows the stomach does this
All of these follow from the same mechanism. These drugs delay gastric emptying deliberately — that is much of how they suppress appetite. Food sits in the stomach longer, which means more time for fermentation and gas, and more pressure sitting below a valve that is supposed to keep things down.
That is also why the sulfurous smell people describe is not imagined. Food lingering in a warm stomach for longer produces sulfur-containing gases, and the burping brings them up. It is unpleasant and it is not a sign of anything sinister.
Everything in that table is downstream of the same thing: a stomach emptying more slowly on purpose.
The dose question, which Zepbound's label answers
Wegovy’s table gives one dose against placebo. Zepbound’s is stratified across 5, 10 and 15 mg, which lets you see whether these effects climb with dose.[2] Mostly, they do not.
| Effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Eructation | 1% | 4% | 5% | 5% |
| Gastroesophageal reflux | 2% | 4% | 4% | 5% |
| Dyspepsia | 4% | 9% | 9% | 10% |
Each of these roughly doubles or triples from placebo to the lowest dose and then flattens. That is a different pattern from fatigue, which keeps climbing with dose. Practically, it means the burping you get at 5 mg is roughly the burping you get at 15 — so if you can tolerate it early, escalation is unlikely to make this specific problem much worse.
What actually helps
There are no trials of remedies for this, so what follows is mechanism-led and modest. It is worth saying plainly rather than dressing up.
- Smaller meals, eaten more slowly. A stomach that empties slowly copes badly with volume, and swallowed air makes burping worse.
- Carbonated drinks add gas to a system already holding it. Cutting them is the single change most people notice.
- Fatty and very large meals sit longest. They also drive reflux independently.
- Do not lie down after eating, which is standard reflux advice and matters more when the stomach is emptying slowly.
For the effects further down the same system, our constipation guide covers what the labels report and what the evidence supports, and how long side effects last covers the escalation-week pattern most of them follow.
Frequently Asked Questions
References
- 1.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 6.1 Adverse Reactions: eructation, dyspepsia, abdominal distension, flatulence and gastroesophageal reflux disease (revised 06/2026) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 2.Eli Lilly and Company. ZEPBOUND (tirzepatide) — US Prescribing Information, Section 6.1 Adverse Reactions, dose-stratified table (SPL effective 2026-04-22) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
Related research
Constipation on a GLP-1: What the Labels Report and What Actually Helps
The Wegovy label reports constipation in 24% against 11% on placebo; the Zepbound label reports it by dose. Here is why it outlasts the nausea, and where the confident advice online runs ahead of the evidence.
6 min read
GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026
The Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels in February 2026, after three large studies looked for a signal and none found one.
7 min read
GLP-1 Hair Loss and Muscle Loss: What Was Measured
Hair shedding and lean-mass loss both appear in the trial record, and both are mostly consequences of losing weight quickly rather than of the drug. That is reassuring about mechanism and not reassuring about outcome, and this holds both.
11 min read
GLP-1 Pancreatitis and Gallbladder Risk: What the Labels Counted
Two labeled warnings that are not the same kind of problem. Gallbladder disease tracks with rapid weight loss and is well counted; pancreatitis is rarer, was an exclusion criterion in the pivotal trials, and the database studies disagree.
12 min read
GLP-1s and Hormonal Birth Control: Which Labels Carry the Warning
The labeled interaction between a GLP-1 and the contraceptive pill belongs to tirzepatide alone. Mounjaro and Zepbound set a four-week window after starting and after every dose increase; the three semaglutide labels carry no such advisory. We read all five to establish which is which.
9 min read
GLP-1s, Pregnancy and Trying to Conceive: What the Labels Say
If you are pregnant or might be, this is a conversation with a clinician. What this sets out is the text behind it: each label's own wording on pregnancy, on the interval before a planned one, and on breastfeeding, plus where the human evidence is genuinely thin.
11 min read
Where to get tirzepatide (Mounjaro / Zepbound) online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Try Ageless
Semaglutide at $119/month, 37% under the register median
From $169/mo
Get started →Trimi Health
Knowing which pharmacy fills the vial — it names VialsRx
From $125/mo
Get started →ShedRx
Oral orforglipron alongside the injectables
From $299/mo
Get started →